NASDAQ:KERX Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free KERX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.97▼$3.4750-Day Range N/A52-Week Range$2.47▼$5.98Volume2.60 million shsAverage Volume1.69 million shsMarket Capitalization$344.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Keryx Biopharmaceuticals alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. KERX Stock News HeadlinesNovember 15, 2023 | morningstar.comXTL Biopharmaceuticals Ltd ADR XTLBSeptember 11, 2023 | investing.comImmuneOnco Biopharmaceuticals Shanghai Inc (1541)March 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.August 13, 2023 | finance.yahoo.comQ2 2023 Westrock Coffee Co Earnings CallJuly 29, 2023 | thestreet.comKeryx CEO vs. a Short-Seller: Zerenex Patent DebateMay 12, 2023 | marketwatch.com8-K: CUTERA INCMay 6, 2023 | seekingalpha.comManoj MadhavanMay 3, 2023 | finance.yahoo.comBiopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and ForecastMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…April 13, 2023 | wsj.comStaidson (Beijing) Biopharmaceuticals Co. Ltd.March 28, 2023 | finance.yahoo.comBiopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight PartnersJanuary 29, 2023 | marketwatch.comBiopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027January 25, 2023 | seekingalpha.comNAVB Navidea Biopharmaceuticals, Inc.January 25, 2023 | finance.yahoo.comBiopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)September 15, 2022 | thestreet.comWell-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug LaunchOctober 26, 2021 | finance.yahoo.comKeryx (KERX) Q1 Loss Wider than Expected, Revenues BeatJuly 29, 2021 | au.finance.yahoo.comTwitter tests notification banner for suspended and locked accountsJuly 29, 2021 | yahoo.comJoey Jordison, Slipknot co-founder and longtime drummer, dies at age 46July 28, 2021 | uk.finance.yahoo.comWhy Starbucks (SBUX) Might Surprise This Earnings SeasonJuly 27, 2021 | uk.finance.yahoo.comUN: World leaders can attend annual UN meeting in personJuly 27, 2021 | nz.finance.yahoo.comCreekstone Farms Meats Sizzle on Yoder Smokers With New PartnershipJuly 27, 2021 | au.finance.yahoo.comMidtown, Atlanta Based Innovien Solutions Continues Growth StreakJuly 27, 2021 | nz.finance.yahoo.comJill Biden Made This Versatile Bag Sell Out, and She Just Wore It AgainJuly 27, 2021 | yahoo.comIt's Your Business | More improvements on tap for Target on North ProspectSee More Headlines Receive KERX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:KERX CUSIP49251510 CIK1114220 Webwww.keryx.com Phone617-466-3500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,440,000.00 Net Margins-96.41% Pretax MarginN/A Return on EquityN/A Return on Assets-60.05% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Sales & Book Value Annual Sales$60.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-28.00Miscellaneous Outstanding Shares102,380,000Free FloatN/AMarket Cap$344.00 million OptionableOptionable Beta2.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 43)Interim CEO & Director Mr. Scott A. Holmes (Age 44)CFO, Sr. VP & Treasurer Ms. Christine A. Carberry (Age 57)Sr. VP & COO Dr. John F. Neylan (Age 65)Sr. VP & Chief Medical Officer Mr. Tony ChambersVP of SalesKey CompetitorsVerastemNASDAQ:VSTMXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLVanda PharmaceuticalsNASDAQ:VNDAMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors KERX Stock Analysis - Frequently Asked Questions How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analyst estimates of $29.56 million. What other stocks do shareholders of Keryx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), Ariad Pharmaceuticals (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX). This page (NASDAQ:KERX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keryx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.